Fig. 1: NeoRHEA clinical study summary. | Nature Communications

Fig. 1: NeoRHEA clinical study summary.

From: Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study

Fig. 1

a Pie plots of baseline clinico-pathological characteristics of all evaluable (n = 97) patients. b Pie plots of ultrasound response post-treatment and Complete Cell Cycle arrest (CCCA) at surgery. c Ki67 percent (%) assessed by immunohistochemistry (IHC) in baseline and surgery tumor samples. d Tumor Infiltrating Lymphocytes (TILs) percent (%) assessed in H&E slides at baseline and surgery tumor samples. For (c, d), each sample is represented by one point; patients with samples in both timepoints (n = 58 patients for Ki67 and n = 76 for TILs) relate to a line, and points are colored according to the presence or not of CCCA. Patients with samples in at least one timepoint: n = 88 for Ki67 and n = 97 for TILs. Box plots show the median (horizontal line), interquartile range (box = 25th to 75th percentile), and whiskers extending to the smallest and largest values within 1.5 ×  QR from the lower and upper quartiles, respectively; points beyond the whiskers represent outliers. Two-sided unpaired Wilcoxon was used, no adjustments were made for multiple comparisons. NA not available data. cT clinical tumor status, cN clinical nodal status. Source data are provided as supplementary Table 1.

Back to article page